GlassScriptPhysician profile
George Kelly
NPI 1619944113
$184,896.25
in general payments reported to CMS, 2019-2025
33 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $13K · 2021: $23K · 2022: $41K · 2023: $13K · 2024: $13K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $7,720 · Travel and Lodging: $1,558 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,325.00 |
| Food and Beverage | $7,720.15 |
| Travel and Lodging | $1,558.31 |
| Education | $124.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101,561.00 | 2019-2025 | |
| Amgen INC. | $22,757.58 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $22,411.74 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $19,499.77 | 2019-2025 | |
| Lilly USA, LLC | $8,666.71 | 2019-2024 | Taltz, Zepbound |
| Ucb, INC. | $3,313.68 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,669.47 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| E.R. Squibb & Sons, L.L.C. | $732.59 | 2019-2025 | Orencia |
| Pfizer INC. | $640.98 | 2019-2024 | |
| Genentech USA, INC. | $461.84 | 2019-2024 | Actemra |
| Aurinia Pharma U.S., INC. | $429.02 | 2021-2023 | |
| Organon LLC | $366.44 | 2021-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $365.09 | 2024-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $355.77 | 2019-2025 | Tymlos |
| Genzyme Corporation | $355.40 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.56 | 2020-2025 | Cyltezo |
| Astrazeneca Pharmaceuticals LP | $206.57 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $181.83 | 2022-2023 | Acthar |
| Sobi, INC | $173.88 | 2019-2025 | |
| Sandoz INC. | $163.26 | 2023-2024 | Hyrimoz |
| Kyowa Kirin, INC. | $93.73 | 2023-2025 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $52.69 | 2019-2023 | Truxima |
| Tersera Therapeutics LLC | $46.28 | 2022 | |
| Celgene Corporation | $43.08 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.12 | 2022-2023 | Strensiq |
| Fresenius Kabi USA, LLC | $30.72 | 2023 | |
| Horizon Therapeutics Plc | $26.00 | 2023 | |
| Medexus Pharma, INC. | $19.66 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.79 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.